Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 18/20 | 0.63 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
| ▸ | TOP2A | P11388 | 1/20 | 0.38 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8100317 | 0.96 | GSK3B (0.64) | GSK3BCACNA1FPOLBMAPK1CACNA1D | |
| SCHEMBL1186908 | 0.96 | GSK3B (0.64) | GSK3BCACNA1FPOLBMAPK1CACNA1D | |
| SCHEMBL1344459 | 0.88 | GSK3B (0.53) | GSK3BCACNA1FPOLBMAPK1CACNA1D | |
| SCHEMBL1186532 | 0.87 | GSK3B (0.52) | GSK3BCACNA1FPOLBMAPK1CACNA1D | |
| SCHEMBL1185345 | 0.87 | GSK3B (0.55) | GSK3B | |
| SCHEMBL8099235 | 0.86 | GSK3B (0.59) | GSK3BCACNA1FPOLBMAPK1CACNA1D | |
| SCHEMBL1185725 | 0.86 | GSK3B (0.63) | GSK3BCACNA1FPOLBMAPK1CACNA1D | |
| SCHEMBL12873913 | 0.86 | GSK3B (0.63) | GSK3BCACNA1FPOLBMAPK1CACNA1D | |
| SCHEMBL8093412 | 0.85 | GSK3B (0.51) | GSK3B | |
| SCHEMBL12873990 | 0.82 | GSK3B (0.72) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2203459-B1 | SPIROCYCLIC AMINOQUINOLONES AS GSK-3 INHIBITORS | KYORIN SEIYAKU KK (JP) | 2016-03-16 | — | — | EP | disclosed |
| US-8901112-B2 | Spirocyclic aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2014-12-02 | — | — | US | disclosed |
| US-8901112-B2 | Spirocyclic aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2014-12-02 | — | — | US | disclosed |
| US-8476261-B2 | Spirocyclic aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-8476261-B2 | Spirocyclic aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-20110034436-A1 | SPIROCYCLIC AMINOQUINOLNES AS GSK-3 INHIBITORS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-02-10 | — | — | US | disclosed |
| US-20110034436-A1 | SPIROCYCLIC AMINOQUINOLNES AS GSK-3 INHIBITORS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-02-10 | — | — | US | disclosed |
| WO-2009035684-A1 | SPIROCYCLIC AMINOQUINOLONES AS GSK-3 INHIBITORS | ACTIVX BIOSCIENCES, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034436-A1 | SPIROCYCLIC AMINOQUINOLNES AS GSK-3 INHIBITORS | GSK3A, GSK3B, GSKIP | GSK3B 2/4885CACNA1F 3651/4885POLB 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.